BAXTER INTERNATIONAL INC Q3 FY2024 earnings call

Management Statement and Operational Highlights

• North Cove Recovery: The North Cove facility, impacted by Hurricane Helene, saw key IV solutions lines restart ahead of schedule, with full production expected by year-end. Global sites were activated to support inventory.
• Third Quarter Performance: Total company sales grew 4% on reported and constant currency basis. MPT grew 7%, HST 1%, Pharmaceuticals 1%, and Kidney Care 5%.
• Strategic Transformations: Pending sale of Kidney Care to Carlyle, realignment of operating model, and divestiture of BioPharma Solutions were highlighted as part of ongoing transformation.
• Operational Initiatives: Focus on supply chain efficiency, cost savings, and new product launches, including the Novum IQ pump platform with growing market share.

Segment Performance

• Medical Products & Therapies (MPT): Sales were $1.3 billion, increasing 7%. This segment led all others with strong growth in infusion therapies, including the Novum IQ pump platform, and advanced surgery products.
• Healthcare Systems & Technologies (HST): Sales were $752 million, up 1%. Growth was driven by US patient support systems but offset by softness in Frontline Care and international markets.
• Pharmaceuticals: Sales were $588 million, up 1%. Double-digit growth in drug compounding offset declines in Injectables & Anesthesia, with a temporary weakness expected to improve.
• Kidney Care: Sales totaled $1.2 billion, increasing 5%. Driven by demand for acute therapies and peritoneal dialysis products, this segment is set to separate as Vantive.

Guidance

• 2024 Full Year: Adjusted for Hurricane Helene, total sales growth is expected to be 1%-2% reported and ~2% constant currency. Continuing operations sales growth is ~2%. Fourth quarter sales expected to decline low-single-digits on reported and constant currency basis.
• 2025 Outlook: Anticipates 4%-5% top line growth and 16.5% adjusted operating margin, with margin expansion thereafter. Includes benefits from pricing, supply chain efficiencies, and expense leverage.

Risks

• Hurricane Impact: Disruption to North Cove production negatively impacted fourth quarter sales and will affect early 2025 results.
• Regulatory and Macroeconomic: Uncertainties in regulatory matters and macroeconomic environment could materially affect results.
• Operational Disruptions: Manufacturing facility disruptions and supply chain issues pose risks to production and inventory levels.

Question and Answer

Q: Travis Steed asked about HST performance and 2025 guidance.

A: Joe Almeida and Joel Grade discussed HST recovery, new product launches in 2025, and margin expectations for 2025.

Q: Pito Chickering inquired about manufacturing diversification and 2025 revenue.

A: Joe Almeida discussed global manufacturing network and restocking potential to offset Hurricane impact.

Q: Vijay Kumar asked about operating margin comparison and free cash flow.

A: Joel Grade discussed margin bridge, cost containment, and free cash flow expectations.

Q: Joanne Wuensch asked about China tariffs and Novum pump uptake.

A: Joe Almeida and Joel Grade discussed China's minimal impact on Baxter and strong uptake of the Novum pump.

Q: Lawrence Biegelsen asked about operating margin bridge and non-operating expenses.

A: Joel Grade and Clare Trachtman discussed margin bridge complexity and interest expense expectations.

Q: David Roman asked about revenue outlook and capital allocation.

A: Joe Almeida and Joel Grade discussed revenue levers from new product launches and capital allocation trajectory for R&D and SG&A.